rontalizumab (101)							9114

Structure	 

Heavy chain / Chaone lourde / Cadena pesada

EVQLVESGGG LVQPGGSLRL SCATSGYTFT EYIIHWVRQA PGKGLEWVAS  50

INPDYDITNY NQRFKGRFTI SLDKSKRTAY LQMNSLRAED TAVYYCASWI 100

SDFFDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150

PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200

NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250

LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300

RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350

LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400

DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447

Light chain / Chaone lygire / Cadena ligera

DIQMTQSPSS LSASVGDRVT ITCRASQSVS TSSYSYMHWY QQKPGKAPKV  50

LISYASNLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQHSWGIPR 100

TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150

QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200

THQGLSSPVT KSFNRGEC                                    218

Disulfide bridges location / Position des ponts disulfure / Posiciones
de los puentes disulfuro

Intra-H	22-96	144-200	261-321	367-425

	22??-96??	144??-200??	261??-321??	367??-425??

Intra-L	23?-92?	138?-198?



	23???-92???	138???-198???



Inter-H-L	220-218?	220??-218???



Inter-H-H	226-226??	229-229??





N-glycosylation sites / Sites de N-glycosylation / Posiciones de
N-glicosilaciun

297, 297??

CAS		948570-30-7

Description

immunoglobulin G1-kappa, anti-[Homo sapiens interferon alpha
(IFN-alpha)], humanized monoclonal antibody;

gamma1 heavy chain [humanized VH (Homo sapiens IGHV3-74*01 (76.30%)
-(IGHD)-IGHJ4*01) [8.8.10] (1-117) -Homo sapiens IGHG1*03, CH1 R120>K
(118-447)], (220-218?)-disulfide with kappa light chain (1'-218')
[humanized V-KAPPA (Homo sapiens IGKV1-39*01 (83.80%) -IGKJ1*01)
[10.3.9] (1?-111?) -Homo sapiens IGKC*01 (112?-218?)];
(226-226":229-229")-bisdisulfide dimer 

immunoglobuline G1-kappa, anti-[Homo sapiens interfyron alpha
(IFN-alpha)], anticorps monoclonal humanisy; 

chaone lourde gamma1  [VH humanisy (Homo sapiens IGHV3-74*01 (76.30%)
-(IGHD)-IGHJ4*01) [8.8.10] (1-117) -Homo sapiens IGHG1*03, CH1 R120>K
(118-447)], (220-218?)-disulfure avec la chaone lygire kappa (1'-218')
[V-KAPPA humanisy (Homo sapiens IGKV1-39*01 (83.80%) -IGKJ1*01) [10.3.9]
(1?-111?) -Homo sapiens IGKC*01 (112?-218?)]; dimire
(226-226":229-229")-bisdisulfure 

inmunoglobulina G1-kappa, anti-[interferun alfa de Homo sapiens
(IFN-alpha)], anticuerpo monoclonal humanizado; 

cadena pesada gamma1 [VH humanizada (Homo sapiens IGHV3-74*01 (76.30%)
-(IGHD)-IGHJ4*01) [8.8.10] (1-117) -Homo sapiens IGHG1*03, CH1 R120>K
(118-447)], (220-218?)-disulfuro con la cadena ligera kappa (1'-218')
[V-KAPPA humanizada (Homo sapiens IGKV1-39*01 (83.80%) -IGKJ1*01)
[10.3.9] (1?-111?) -Homo sapiens IGKC*01 (112?-218?)]; dnmero
(226-226":229-229")-bisdisulfuro 

	

WHO 

International Nonproprietary Names Programme	

15/07/2009

p.   PAGE  1 /2



		

